Wong Seng Weng, MBBS, MRCP, FAMS - Treatment Approaches in EGFR-Mutant NSCLC Post-TKI and Chemotherapy: What Now and What Next?

Visit https://www.peervoice.com/FQC860 to view the entire programme with slides. After completing “Wong Seng Weng, MBBS, MRCP, FAMS - Treatment Approaches in EGFR-Mutant NSCLC Post-TKI and Chemotherapy: What Now and What Next?”, participants will be able to: Recognise current unmet needs for patients with EGFR-mutant NSCLC who progress after multiple lines of therapy; Assess the clinical relevance of available safety and efficacy data evaluating novel therapies in patients with EGFR-mutant NSCLC who have progressed following TKI therapy and chemotherapy; and Identify evidence-based best practices for managing patients with EGFR-mutant NSCLC who have progressed following TKI therapy and chemotherapy.